" />
Therapeutic Breast/Ovarian/Prostate Peptide Cancer Vaccine DPX-0907 - CISMeF
Therapeutic Breast/Ovarian/Prostate Peptide Cancer Vaccine DPX-0907NCIt concept
Preferred Label : Therapeutic Breast/Ovarian/Prostate Peptide Cancer Vaccine DPX-0907;
NCIt definition : A lipid-based multi-peptide cancer vaccine targeted against multiple cancers with
immunopotentiating activity. Therapeutic breast/ovarian/prostate peptide cancer vaccine
DPX-0907 is a lyophilized liposomal proprietary preparation comprised of 7 tumor-specific
HLA-A2-restricted epitopes (TAAs): Topoisomerase II alpha, B-cell receptor-associated
protein 31 (CDM protein), TNF-alpha-converting enzyme (TACE/ADAM17), Abelson homolog
2 (Abl2), gamma catenin (Junction plakoglobin), epithelial discoidin domain receptor
1 (EDDR1) and integrin beta 8 subunit. Upon vaccination, the lyophilized antigen/adjuvant/liposome
complex is re-suspended in Montanide 1SA51 VG to create a depot effect, thereby presenting
the TAAs to the immune system for a prolonged period of time. This may stimulate a
potent cytotoxic T-lymphocyte (CTL) immune response against cancer cells that express
these 7 TAAs and share epitopes with the vaccine epitope peptides, resulting in tumor
cell lysis. The 7 TAAs are overexpressed on the surface of breast/ovarian and prostate
cancer cells and play an important role in tumor cell growth and survival.;
Semantic type(s)